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codes as independent variables and the logit of progression degree as a dependent 
variable. Results: 1,436 target patients were extracted from the database. When 
the actual progression degree is over 80%, the estimated progression degree rises 
with the actual degree, however, at the lower progression degrees, the estimated 
degree was excessively overestimated. ConClusions: We have developed a model 
to estimate the progression degree in colon cancer. The model estimates the pro-
gression degree well only for the last phase patients. The model should further be 
improved to minimize the bias at the lower degree.
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objeCtives: Overall survival (OS) remains the gold standard measure of clini-
cal efficacy for oncology clinical trials due to its objective nature and consistency 
between diseases and treatments. However, given recent advances in treatments, 
and prolonged survival, OS benefits are becoming more challenging to establish, 
requiring more extensive follow-up. A number of methods to test this rationale 
have been developed but these often lack adequate data, relying solely on mean or 
median survival. Recognising these limitations, we developed an alternative meth-
odology whereby surrogacy is established over time, to ensure that a surrogate is 
not only valid at the mean, but also throughout treatment duration. Methods: A 
number of different survival points were derived from selected oncology trials by 
digitizing available survival curves. PlotDigitizer 2.6.4 software was used to establish 
time points for 10%, 25%, 50%, 75%, and 90% OS and progression-free survival (PFS). 
Correlation and regression analysis were evaluated at these percentiles based on 
survival times. Patient populations between the clinical trials were comparable to 
one another. Statistical analysis was conducted in STATA 12. Results: Correlation 
analysis found the strongest association between PFS and OS between 75% and 
25% survival (0.865 to 0.953; p< 0.01), with a weak association at 90% survival (0.61; 
p= 0.096). Regression analysis also found that PFS had the largest influence on OS 
between 75% and 25% survival (R2> 0.75). ConClusions: Given the varying nature 
of how patients progress across and within types of therapies, it is essential to 
ensure the surrogacy of the endpoint across the full trial duration. For example, 
patients may progress early on in a disease and surrogacy may not be consistent 
across different time points. Additionally, in evaluating older studies, using this 
approach of scanning survival data will provide a richer picture of the disease area 
that may no longer be available from authors or research institutions.
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bACkgRound: Overactive bladder(OAB) is characterized by symptoms of urgency, 
incontinence, frequency and nocturia. With the syndromic nature of the condition, 
clinical trials often solely report the most effective outcome i.e. the symptom with 
the largest improvement. As a result different interventions are evaluated for dif-
ferent outcomes, which can have severe implications for network meta-analyses, 
and consequently, decision-making. objeCtives: To evaluate the use of multivari-
ate network meta-analysis(MVNMA) to identify the most effective intervention for 
treating OAB syndrome. Methods: Using Bayesian Markov Chain Monte Carlo 
methods, we developed MVNMA accounting for the correlation between multiple 
outcomes to predict treatment effects for missing data. We extended this model to 
incorporate the exchangeability between treatment effects of the same interven-
tion with different methods of administration (e.g. immediate release, extended 
release, intravesical etc.) and incorporated dose-response constraints on increasing 
doses. The outcomes of interest were mean change from baseline in incontinence, 
and urgency episodes. Results: Independently, the datasets included 109 and 56 
trials, evaluating 93 and 51 interventions, for incontinence and urgency episodes 
respectively. Sacral nerve stimulation appeared to be the most effective intervention 
for reducing incontinence with an estimated mean reduction of -8.9(95%CrI:-10.9,-
7) episodes per 24hours relative to placebo. For urgency, sacral nerve stimulation 
was disconnected from the network and thus could not be not evaluated. Borrowing 
information between outcomes, the dataset for multivariate analyses included 117 
trials evaluating all 95 treatments for OAB. Sacral nerve stimulation appeared to be 
the most effective intervention for both incontinence and urgency episodes with an 
estimated mean reduction of -8.3(95%CrI:-10.1,-6.9) and -9.1(95%CrI:-10.5,-7.3) epi-
sodes, respectively. ConClusions: Sacral nerve stimulation appeared to be the most 
effective intervention for treating OAB symptoms. MVNMA allowed us to evaluate 
all interventions across all outcomes, and in this case also increased precision in 
treatment effect estimates. Further work includes adjustment for baseline severity.
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objeCtives: The clinical endpoints selected for oncology trials have to meet the 
needs of diverse stakeholders: patients, clinicians, regulators, and HTA agencies, each 
with a different perspective. PFS is becoming a more widely accepted measure of 
treatment efficacy, but there is tension between regulators and payors regarding its 
acceptability. This study investigated PFS as a valid and credible endpoint from the 
perspectives of relevant decision-makers. Methods: Published and gray literature 
(2005–2015) were searched for regulatory and HTA guidance on PFS as an endpoint. 
We identified examples of decisions by regulators and HTA agencies in which PFS 
tended to be protective of discontinuations due to adverse events relative to stand-
ard dose EFV. Use of arm-specific regression supplemented by endonodal trials led 
to tighter confidence intervals facilitating decision-making. Specifically, DTG was 
consequently superior to EFV with respect to CD4 cell counts and raltegravir was 
distinguishable from EFV when it was not otherwise. ConClusions: Making full 
use of available evidence is the focal strength of NMA methodology. Therefore, we 
recommend use of endonodal trials to further supplement evidence bases requiring 
arm-specific meta-regression.
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objeCtives: In an absence of randomized controlled trials (RCTs) and to verify RCT 
evidence, health technology assessment (HTA) agencies commonly rely on real-
world (RW) studies to provide efficacy evidence for healthcare interventions. RW 
study designs can introduce considerable bias into a systematic review (SR) and sev-
eral methodologies exist to evaluate the risk of bias in such studies. We conducted a 
series of reviews to identify which tools are commonly used and which are recom-
mended by HTA bodies. Methods: A targeted search of SRs including RW studies, 
conducted in MEDLINE and EMBASE (OVID SP), identified reviews published January 
2013-June 2015. Studies identified were reviewed to determine which appraisal tool 
was used. Secondly, recommendations for the critical appraisal of RW studies by 
expert review groups (Cochrane, CRD) and HTA bodies (NICE, SMC, NCPE, AWMSG, 
IQWiG, PBAC, AMCP, AHRQ and CADTH) were reviewed. Results: 1885 studies were 
identified and screened. Commonly used tools included Downs & Black, Chalmers, 
the Newcastle-Ottawa Scale, and the CriSTal checklist. Neither Cochrane nor CRD 
recommend a particular risk of bias instrument. The AHRQ developed the MORE 
checklist following a SR of existing critical appraisal tools. Of the other HTA bodies 
only CADTH recommend use of a specific critical appraisal tool; SIGN 50 (for cohort 
or case-control studies). The tools identified examine a variety of criteria including 
reporting, external validity, bias, confounding, and power. ConClusions: There 
is no consensus on a preferred instrument that allows for the assessment of all 
types of RW evidence and critical appraisal of RW evidence is often omitted from 
HTA submissions. There is thus a need for cross communication between groups 
to reach a consensus and develop a suitable tool. Until a suitable tool is developed, 
reviewers should select the most appropriate checklist for the design of the studies 
identified in a particular SR.
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objeCtives: Sample quality in prospective long-term drug safety studies can 
be impaired by selective lost-to-follow-up. Attrition will especially bias the sam-
ple, when patients with relevant risk factors selectively drop out. In this case, 
effects in endpoints cannot be related to study-relevant independent variables. 
The present contribution will demonstrate how careful follow-up procedures can 
prevent disease-related drop-out bias of the sample. Methods: For a long-term 
prospective safety study of new Oral Contraceptive (OC) 25,213 women aged 20 
to 40 years were enrolled from gynecological practices in Germany. The women 
filled-in a baseline questionnaire and were followed-up over two years with four 
follow-up questionnaires in total. Whenever safety-relevant signs were reported in 
the questionnaires, physicians validated the report. After two years 12,823 women 
were still in the sample and completed the fourth questionnaire. Disease differ-
ences between the “Retained” and the “Lost” group, which could indicate sample 
bias, were analysed using multivariate methods. Results: The “retained” and the 
“lost-to-follow-up” group did not differ in initial disease status or in risk factor at 
study start: High blood pressure: 2.9% in “Retained Group”; 2.7% in “Lost Group” 
(phi= .006; n.s.), diabetes : 0.6% vs. 0.6% (phi= .001; n.s.), high cholesterol: 2.6% vs. 
2.4% (phi= .007; n.s.),venous thrombosis : .8% vs. .8% (phi= .002; n.s.), smoker-rate : 
34.9% vs. 42.3% (phi= .127), BMI> 30: r= .004 (n.s.), age r= .048 (n.s.). The results show 
that drop-out of the initial sample is not related to study relevant morbidity and 
that sample bias cannot be concluded. ConClusions: Careful follow-up methods 
guarantee low lost-to-follow-up in longterm prospective studies of drug safety. 
Since drop-out cannot be attributed to study-relevant confounders, attrition does 
not lead to sample bias.
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objeCtives: Accurate determination of the progression degree in colon cancer is 
of paramount importance for the decision making in treatment policy. However, 
it had been difficult to extract the exacerbation status from the real-world data. 
The objective of the study was to develop the model to determinate the progres-
sion degree using the insurance benefits data in Japan. Methods: We conducted 
analyses using claims data provided by Medical Data Vision Co., Ltd. We extracted 
target patients by the criteria those who meets all of the following conditions; 
at least one colon cancer diagnosis (ICD-10 code C18~20), tractable from the first 
diagnosis to death, and have at least 365 days of observation. We set the progression 
degree as a scale from 0% to 100%. The degree of 100% indicates the patient death. 
For the first diagnosis, the scale was adjusted based on the patient’s condition. We 
have developed a linear regression model by using the medication frequency of ATC 
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objeCtives: Succinic acid as endogenous metabolite, has a wide range of applica-
tions in medical care. We conduct research on the development of new medicines 
based on succinic acid, ascorbic acid and rutin for the prevention and treatment of 
influenza. A systematic review was carried out to perform a qualitative assessment 
of succinic acid adding in the various medicines and to determine of their phar-
macological action. Methods: MEDLINE®, EMBASE®, Scopus, Cochrane Library 
databases and clinical trials registers between 1966 and Jun 2015 were performed. 
To analyze the RCT were selected and Review on the Study of the pharmacological 
action of drugs, which include succinic acid. Quality of evidence was assessed and 
each article was rated of quality. Results: Our study included 29 articles (23 RCT 
and 6 Review). The evidence varied in terms of: scope and years of research, type 
of treatment, study duration, sample size (< 100 to> 500 patients). Generally, the 
mean age of included patients was middle. For pharmacological properties and by 
relevance RCT are grouped as follows: antigypoxic action were 7 RCT (2003-2013 
years), improve iron absorption in the gastrointestinal tract - 6 RCT (1966-1974), 
hepatoprotective - 4 RCT (2013-2014 years). One RCT proves the efficiency of suc-
cinic acid used in gastroenterology (a combination with omeprazole, 2012), depres-
sion (2013), in transplantation (1993) at menopause (2008), renal failure (2013), to 
improve body temperature during surgery (2007). Analysis of Review opens the new 
prospects for the use of succinic acid in cancer, diabetes and hepatitis C treat-
ment. ConClusions: A comprehencive overview of these studies estimated the 
evidence of succinic acid addition of the drugs. Succinic acid as endogenous metabo-
lite, is a part of drugs of different pharmacological actions. These clinical trial results 
have been retrieved and give the possibility to develop of new drugs with succinic 
acid also in Ukraine.
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bACkgRound: The Parkinson’s Kinetigraph (PKG) is the first device that objec-
tively measures treatable Parkinson’s Disease (PD) symptoms in daily living. 
Collected symptom scores – Bradykinesia [BKS], Dyskinesia [DKS], and Fluctuation 
[FDS] – have been validated and correlate with PD reference standard instru-
ments (UPDRS, AIMS, Patient Diaries). The PKG is used globally – in Europe, 
Asia-Pacific, and the USA. There is a de-identified central repository of all PKG 
reports. objeCtives: Using the central repository, to assess whether patients 
who received a PKG analysis in routine care featured improved PD symptom scores 
over time. Methods: PD patients who had 2+ PKGs within a 6-month time frame 
were eligible for analysis. A total of 591 patients were included and split into 
“controlled” and “uncontrolled” at baseline (first PKG), based on pre-defined cut-
off scores for BKS (23) or DKS (5); for FDS, a normal range was defined, above and 
below which patients were considered uncontrolled. The Mann-Whitey U test 
was used for analysis. Results: For those patients featuring scores considered 
“uncontrolled” (BKS high, DKS high, FDS low or high) at baseline, a statistically and 
clinically significant improvement, on average, was recorded for that score in their 
second PKG in all 4 subgroups (p< 0.01). For those patients with uncontrolled FDS 
at baseline, 43% (FDS low) and 34% (FDS high) had scores considered controlled 
in their second PKG; regarding high DKS, 69% showed some improvement. All 
improved scores were sustained or somewhat augmented on average in those 
patients having more than 2 PKGs. ConClusions: The analysis suggests that 
adding a PKG to a PD patient’s therapy management may significantly improve, 
and subsequently sustain, patient PD scores over time. This is important as, due 
to natural PD progression, one would expect PKG symptom scores to deteriorate 
over time. Other potential PKG benefits were not part of this analysis.
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objeCtives: Spasticity is one of the well-recognized complications of stroke which 
may give rise to pain and limit patients’ ability to perform daily activities. The pre-
disposing factors and direct effects of post-stroke spasticity (PSS) also involve high 
management costs in terms of healthcare resources and case-control designs are 
required for establishing such differences. In ‘The Health Improvement Network’ 
(THIN) database, such a study was difficult to provide reliable estimates since the 
prevalence of post-stroke spasticity was found to be substantially below the most 
conservative previously reported estimates. The objective of this study was to use 
predictive analysis techniques to determine if there were a substantial number of 
potentially under-recorded patients with PSS. Methods: This study used retrospec-
tive data from adult patients with a diagnostic code for stroke between 2007 and 
2011 registered in THIN. Two algorithm approaches were developed: 1) a statistically 
validated data-trained algorithm using machine techniques and 82 potential predic-
tors; and 2) a clinician-trained algorithm based on the review of 200 stroke cases 
by two expert neurologists. The algorithm with the better performance was used 
to identify PSS cases. Results: In THIN data, 45,613 stroke events were identified, 
with 660 having a diagnosis PSS. A data-trained algorithm using Random Forest 
showed better prediction performance than the clinician-trained algorithm, with 
higher sensitivity and only marginally lower specificity. Overall accuracy was 84% 
and 72%, respectively. The data-trained algorithm predicted an additional 3,912 
records consistent with patients developing spasticity in the 12 months following a 
stroke. ConClusions: Using machine learning techniques, additional unrecorded 
post-stroke spasticity patients were identified, increasing the condition’s prevalence 
was the primary endpoint, and compared the assessments. Results: Guidance from 
regulatory and HTA agencies indicates the suitability of PFS as an endpoint depends 
on the cancer type and stage, seen in assessments of afatinib and erlotinib in non-
small cell lung cancer and bevacizumab in ovarian cancer: FDA and EMA approvals 
were based on PFS data. However, the TC in France awarded ASMR IV for erlotinib and 
bevacizumab and ASMR V for afatinib. NICE in the UK approved afatinib and erlotinib 
based on additional interim OS data and a patient access scheme; bevacizumab was 
not approved because of uncertainty in translating PFS gain to OS. ConClusions: 
PFS is a valid and credible endpoint in many oncology trials. However, differences 
in stakeholder perspectives and evidentiary requirements may mean that products 
approved on the basis of PFS data face delays in HTA or protracted pricing negotia-
tions, or are rejected for reimbursement. PFS as an endpoint allows shorter trials , 
efficiency is improved, and fewer patients are exposed to an investigational drug. 
The limitations associated with PFS as an endpoint are largely manageable. Thus, the 
value and relevance of PFS needs to be recognized consistently across HTA agencies, 
and approaches harmonized between HTA agencies and regulators.
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objeCtives: To elicit a comprehensive stakeholder view on the acceptability of using 
real-world evidence (RWE) for informing trial design and establishing relative effec-
tiveness (RE) of new medicines in regulatory and HTA assessments. Methods: IMI 
GetReal (www.imi-getreal.eu) is facilitating stakeholder dialogue on the role of RWE 
through case studies which focus on RE issues in several disease areas. In a series of 
pilot workshops, stakeholders considered challenges in establishing the RE of multiple 
sclerosis (MS) medicines. Alternative solutions were proposed for using RWE to miti-
gate these challenges: participants provided views on the usefulness and acceptability 
of solutions and the potential impact on regulatory and reimbursement decision 
making. Results: Three approaches were proposed: 1) supplementing trial results 
with RWE in network meta-analysis (NMA) to generate RE estimates; 2) incorporating 
RWE in NMA to support simulations informing trial designs; 3) using risk equations 
derived from RWE to inform risk stratified trial designs. Stakeholders cautiously wel-
comed the proposals as additional options for reducing decision-making uncertainty, 
raising the key issue of potential biases that could be introduced by including RWE in 
these ways. The inclusion of RWE would most likely be considered as supportive of or 
adding context to regulatory submissions, but could be more central in HTA decision 
making and early medicine development if appropriate quality control measures 
are put in place to mitigate biases commonly associated with non-interventional 
data. ConClusions: For the use of RWE to become more acceptable by decision mak-
ers, standard methods for data synthesis should be developed, as well as guidelines 
to ensure transparency in selection of data sources and data synthesis. The GetReal 
consortium provides a ‘safe harbour’ for stakeholders to discuss the potential use of 
RWE for decision making, and further work is ongoing to develop methods for the 
‘early’ use of RWE and to foster dialogue between stakeholders.
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objeCtives: Objective of this study was to provide a baseline against which 
to monitor trends in breast cancer awareness and the effect of interventions to 
promote breast cancer awareness. Methods: A cross sectional house hold survey 
was conducted on 365 young women between the age group of 18-40 in urban and 
rural areas of South India using a validated questionnaire. Results: A total of 99% 
respondents knew that breast cancer is the leading cancer with a mean knowl-
edge of 73.7±15.1% for urban and 47.2±13.9% for rural women. Sources of infor-
mation for their knowledge were mainly health professionals/workers (98.2%), 
friends/neighbors (83.5%), TV/Radio (76.0%) and printed materials (60.2%). Rural 
women had significantly less awareness compared to urban women. Majority 
of the respondents knew the risk factors of breast cancer aging (69%), nullipar-
ity (56.4%), delivery at more than 30 years old (46%), shorter duration of breast 
feeding (72.0%), contraceptive pills (46.0%), obesity (80.0%), big breast (81%), hor-
mone replacement therapy (HRT) (54.4%), menopause after the age of 50 (20%) and 
menarche before age 11(34.8%). most of the respondents agreed that the following 
are risk factors smoking (85.2%), alcohol intake (86.8%) and exposure to radiation 
(67.2%).the rural respondents strongly believed that breast cancer with wearing 
of underwire bra (34.3%) but most of the urban respondents not believed (65.6%).
Regarding awareness of the screening methods, 66% and 49% were aware about 
BSE and CBE respectively, 78% were aware about mammography. ConClusions: 
The study showed awareness of breast cancer and practice of screening procedures 
increases with higher education and urban living. Therefore, there is an urgent 
need to conduct breast cancer awareness camps in rural areas for an intensive 
breast cancer awareness campaign and availability of screening centers prioritized 
in rural areas.
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